A federal court handed the FDA and Eli Lilly a major win in a case challenging the end of the tirzepatide shortage. On Wednesday, The US District Court for the Northern District of Texas denied …
WeightWatchers files for bankruptcy amid pressure from weight-loss drugs The Washington Post WeightWatchers Files Bankruptcy to Adapt to Chemically Induced Weight-Loss Future WSJ WeightWatchers Files for Bankruptcy to Reduce $1 Billion in Debt The New York Times WeightWatchers Files Bankruptcy After Growth in GLP-1 Drugs Yahoo Finance WeightWatchers goes bankrupt as offering GLP-1 drugs couldn’t cure debt problems MarketWatch
WeightWatchers (WW) announced Tuesday that it is filing for bankruptcy in an attempt to crawl out of more than $1 billion in debt. The news comes as the company is amid a refocus on prescribing weight-loss GLP-1 drugs like Ozempic. Read more…
Here’s our initial take on Novo Nordisk‘s (NYSE: NVO) fiscal 2025 first-quarter financial report. Key Metrics Metric (all figures in Danish kroner) Q1 2024 Q1 2025 Change vs. Expectations Revenue 65.35 billion 78.09 billion 19% Missed Earnings per share 5.68 6.53 15% Beat Operating profit 31.85 billion 38.79 billion 22% n/a Obesity care sales 11.2 … Read more
As the U.S. GLP-1 market is in a period of transition, Novo Nordisk is holding out hope for faster growth in the second half of 2025.